Study evaluated differences in survival with respect to the time interval between tumor resection and initiation of postoperative chemotherapy in patients with NSCLC.
The American Society of Clinical Oncology, American Society for Radiation Oncology, and Society of Surgical Oncology have issued a joint consensus guideline update for the use of radiotherapy following mastectomy in patients with breast cancer.
Cognitive decline associated with adjuvant chemotherapy was more likely to occur in older patients, particularly those whose treatment included docetaxel.
A very large retrospective study of patients with stage II colon cancer found adjuvant therapy improves survival, regardless of treatment regimen, patient age, or high-risk pathologic risk features.
Adjuvant chemotherapy administered during and after radiotherapy is feasible for the treatment of patients with high-risk endometrial cancer despite an increased risk of toxicities compared with radiotherapy alone.
Adjuvant chemotherapy in patients with stage Ib non-small cell lung cancer improved overall survival and 5-year overall survival.
In patients with completely resected stage IB NSCLC, adjuvant chemotherapy is associated with improved survival regardless of tumor size.
Most patients with resected non-small cell lung cancer (NSCLC) preferred a collaborative role in decision-making about adjuvant chemotherapy.
The accuracy of axillary staging and of pathologic evaluation of clinically node-positive breast cancer is improved by a new procedure, reducing the need for a more invasive procedure with debilitating complications.
Women are prescribed adjuvant therapies after breast cancer surgery to reduce the risk of cancer recurrence. The effects of these therapies have been assumed to remain constant over time, but a new study suggests the opposite is true.
Use of adjuvant systemic therapy for localized gastrointestinal stromal tumors has significantly increased over time and patients treated with the therapy have improved survival over surgery alone, according to study data.
Diffuse optical spectroscopic tomographic imaging (DOST) may be useful in predicting which patients will best respond to chemotherapy used to reduce breast cancer tumors before surgery, according to a new study.
The addition of trastuzumab to chemotherapy significantly improved the overall and disease-free survival of women with early stage HER2-positive breast cancer.
Addition of the experimental drug cediranib to standard chemotherapy improves tumor shrinkage and adds a modest improvement in progression-free survival for patients with cervical cancer that has recurred after treatment.
Adding carboplatin and/or bevacizumab to the standard treatment regimen significantly improved pathologic complete response rates in patients with triple-negative breast cancer, according to a new phase 2 study.
A subset of patients with stage III colon cancer had improved survival rates when treated with irinotecan-based therapy, according to recent research.
Scientists have identified a protein that could help doctors decide which patients with bladder cancer would benefit from a treatment that makes radiotherapy more effective, according to a new study.
Contrary to treatment guidelines for high-risk bladder cancer, chemotherapy before or after surgery is not commonly used in routine clinical practice.
Breast cancer patients with high levels of vitamin D in their blood are twice as likely to survive the disease, according to a recent meta-analysis.
Sequentially combining gemtuzumab ozogamicin and standard chemotherapy provides no benefit for older patients with acute myeloid leukemia.
This fact sheet defines adjuvant therapy for breast cancer and explains the length of treatment, which patients are best suited for this treatment, side effects, and highlights current research.
Adding the ESA epoetin alfa to the chemotherapy regimen for high-risk breast cancer improved hemoglobin levels for patients, but it also resulted in increased thrombosis.
A prospective clinical trial conducted in France found that children with low-risk retinoblastoma do not need adjuvant chemotherapy to prevent disease recurrence or metastasis.
Patients with early-stage HER2-positive breast cancer should still receive 1 year of adjuvant trastuzumab as the standard of care, according to data from the phase III HERA trial.
The American Society of Clinical Oncology has released a nearly 100-page report detailing the year's most significant developments in cancer.
Heart failure is relatively common in older women undergoing breast cancer treatment, but trastuzumab therapy appears to raise the risk even more.
A new study suggests radiotherapy may hold clinical promise for the control of local lymph node bed recurrence of malignant melanoma.
Women 60 years and older who received no systemic adjuvant therapy for early-stage breast tumors were at no greater mortality risk than similarly aged women in the general population.
- Ruxolitinib May Improve Symptom Control in Patients With CLL
- 3-drug Regimen With Ricolinostat Active, Safe in Multiple Myeloma
- Lung Cancer Navigator App Aims to Help Patients Understand Disease
- Racial Disparities Persist in Myeloma Treatment Use
- Adding Bortezomib to Rd Improves PFS, OS in Newly Diagnosed Myeloma
- Optimal Timing of Influenza Vaccination in Patients Receiving Chemotherapy
- Racial Disparities Persist in Myeloma Treatment Use
- Hypnosis and Its Use in Cancer Treatment
- Longer Dosing Interval of Zoledronic Acid May Be Acceptable for Bone Metastases
- Melanoma Incidence Still on the Rise in Parts of the United States
- Frailty Classifications Associated With Prognosis Among Older Patients
- Beach Umbrella Not Enough for Protection from UV Rays
- Comprehensive Report Looks at Benefits and Harms of Medical Cannabis
- ASCO: Moderate Activity Linked to Longer Survival in Advanced CRC
- MABp1 Improves Symptoms vs Placebo in Colorectal Cancer
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|